Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand?
Open Access
- 5 February 2020
- Vol. 12 (2), 367
- https://doi.org/10.3390/cancers12020367
Abstract
Venous thromboembolism (VTE), comprising deep-vein thrombosis and pulmonary embolism, is a frequent complication in ambulatory cancer patients. Despite the high risk, routine thromboprophylaxis is not recommended because of the high number needed to treat and the risk of bleeding. Two recent trials demonstrated that the number needed to treat can be reduced by selecting cancer patients at high risk for VTE with prediction scores, leading the latest guidelines to suggest such an approach in clinical practice. Yet, the interpretation of these trial results and the translation of the guideline recommendations to clinical practice may be less straightforward. In this clinically-oriented review, some of the controversies are addressed by focusing on the burden of VTE in cancer patients, discussing the performance of available risk assessment scores, and summarizing the findings of recent trials. This overview can help oncologists, hematologists, and vascular medicine specialists decide about thromboprophylaxis in ambulatory cancer patients.This publication has 85 references indexed in Scilit:
- Prevention of VTE in Nonsurgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- Serum Platelet Factor 4 Is an Independent Predictor of Survival and Venous Thromboembolism in Patients with Pancreatic AdenocarcinomaCancer Epidemiology, Biomarkers & Prevention, 2010
- Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006British Journal of Cancer, 2010
- Increased microparticle tissue factor activity in cancer patients with Venous ThromboembolismThrombosis Research, 2010
- P-selectin/ PSGL-1 Inhibitors versus enoxaparin in the resolution of venous thrombosis: A meta-analysisThrombosis Research, 2010
- Assessing Risk of Venous Thromboembolism in the Patient With CancerJournal of Clinical Oncology, 2009
- Development and validation of a predictive model for chemotherapy-associated thrombosisBlood, 2008
- Tissue factor expression as a possible determinant of thromboembolism in ovarian cancerBritish Journal of Cancer, 2007
- Mapping the EQ-5D Index from the SF-12: US General Population Preferences in a Nationally Representative SampleMedical Decision Making, 2006
- Preference-Based EQ-5D Index Scores for Chronic Conditions in the United StatesMedical Decision Making, 2006